Overall, our study warrants more in-depth tests of the efficacy and mechanisms of action of combining MEKi+HDACi and HDACi+BCL-2 family inhibitors in GBM, possibly by employing local drug delivery or intrathecal chemotherapy to circumvent the blood–brain barrier [67,78,79,80]. The gene discussed is BCL2; the disease is glioblastoma.